Trial · NCT01556763
Results by group53
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 53
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. | Placebo | Serious Adverse Events | 0 | 0 | participants |
| Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. | EVP-6124 (1.0 mg/Day) | Serious Adverse Events | 0 | 0 | participants |
| Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. | EVP-6124 (0.3 mg/Day) | Serious Adverse Events | 1 | 0 | participants |
| Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. | Placebo | Non-Serious Adverse Events | 0 | 0 | participants |
| Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. | EVP-6124 (1.0 mg/Day) | Non-Serious Adverse Events | 5 | 0 | participants |
| Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. | EVP-6124 (0.3 mg/Day) | Non-Serious Adverse Events | 5 | 0 | participants |
| Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. | Placebo | No Adverse Events Reported | 4 | 0 | participants |
| Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. | EVP-6124 (1.0 mg/Day) | No Adverse Events Reported | 4 | 0 | participants |
| Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. | EVP-6124 (0.3 mg/Day) | No Adverse Events Reported | 3 | 0 | participants |
| EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Aripiprazole | EVP-6124 (1.0 mg/Day) | Day 1 | 581.0 | Standard Deviation 149.8 | pg/mL |
| EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Aripiprazole | EVP-6124 (0.3 mg/Day) | Day 1 | 210.0 | Standard Deviation 39.3 | pg/mL |
| EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Aripiprazole | EVP-6124 (1.0 mg/Day) | Day 21 | 2058.6 | Standard Deviation 393.2 | pg/mL |
| EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Aripiprazole | EVP-6124 (0.3 mg/Day) | Day 21 | 968.3 | Standard Deviation 90.1 | pg/mL |
| EVP-6124 Time to Maximum Concentration (Tmax), Patients on Aripiprazole | EVP-6124 (1.0 mg/Day) | Day 1 | 8.0 | Full Range 2 to 8 | hr |
| EVP-6124 Time to Maximum Concentration (Tmax), Patients on Aripiprazole | EVP-6124 (0.3 mg/Day) | Day 1 | 8.0 | Full Range 6 to 8 | hr |
| EVP-6124 Time to Maximum Concentration (Tmax), Patients on Aripiprazole | EVP-6124 (1.0 mg/Day) | Day 21 | 6.0 | Full Range 2 to 8 | hr |
| EVP-6124 Time to Maximum Concentration (Tmax), Patients on Aripiprazole | EVP-6124 (0.3 mg/Day) | Day 21 | 8.0 | Full Range 1 to 8 | hr |
| EVP-6124 Area Under the Curve (AUC[0-24 h]), Patients on Aripiprazole | EVP-6124 (1.0 mg/Day) | Day 1 | 10,966 | Standard Deviation 2831 | pg*hr/mL |
| EVP-6124 Area Under the Curve (AUC[0-24 h]), Patients on Aripiprazole | EVP-6124 (0.3 mg/Day) | Day 1 | 3838 | Standard Deviation 1044 | pg*hr/mL |
| EVP-6124 Area Under the Curve (AUC[0-24 h]), Patients on Aripiprazole | EVP-6124 (1.0 mg/Day) | Day 21 | 42,042 | Standard Deviation 9623 | pg*hr/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01556763/results